Welcome to our dedicated page for MESA LABORATORIES /CO/ SEC filings (Ticker: MLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MESA LABORATORIES /CO/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MESA LABORATORIES /CO/'s regulatory disclosures and financial reporting.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Capone Mark Christopher reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director Mark Christopher Capone received a grant of 2,423 Restricted Stock Units (RSUs) on September 9, 2026. Each RSU represents a contingent right to receive one share of the company’s common stock and is scheduled to vest on September 9, 2027. Following this award, he holds 2,423 RSUs directly. No Rule 10b5-1 trading plan is reported.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Ladiwala Shiraz Shabanali reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director Shiraz Shabanali Ladiwala received a grant of 2,510 Restricted Stock Units (RSUs) on September 9, 2026. Each RSU represents a contingent right to receive one share of common stock and vests on September 9, 2027. Following this grant, Ladiwala holds 2,510 RSUs directly, and no Rule 10b5-1 trading plan is reported.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Alltoft Jennifer Sadie reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director Jennifer Sadie Alltoft received a grant of 1,774 Restricted Stock Units (RSUs) on September 9, 2009. Each RSU represents a contingent right to receive one share of common stock and vests on September 9, 2027. After this award, she holds 1,774 RSUs directly, and no Rule 10b5-1 plan is reported.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Hall Shannon reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director Shannon Hall received a grant of 1,774 Restricted Stock Units (RSUs) on September 9, 2026. Each RSU represents a contingent right to receive one share of common stock and is scheduled to vest on September 9, 2027, resulting in direct ownership of 1,774 RSUs following the award.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Sullivan John James reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director John James Sullivan received a grant of 1,774 Restricted Stock Units (RSUs) on September 9, 2026. Each RSU represents a contingent right to receive one share of common stock and is scheduled to vest on September 9, 2027, resulting in direct holdings of 1,774 RSUs.
MESA LABORATORIES INC (symbol: MLAB) is the issuer of record for a Form 4 filing submitted to the SEC. Tripeny R Tony reported acquisition or exercise transactions in this Form 4 filing.
MESA LABORATORIES INC (MLAB) reported that director R. Tony Tripeny received a grant of 1,774 Restricted Stock Units (RSUs) on September 9, 2026. Each RSU represents a contingent right to receive one share of Mesa Laboratories common stock and vests on September 9, 2027. Following this award, the reporting person holds 1,774 RSUs directly. No transactions were made under a Rule 10b5-1 trading plan.
MESA LABORATORIES, INC. (MLAB) reported the results of its September 8, 2026 annual meeting of shareholders. Holders of 5,595,869 common shares were entitled to vote, and 4,872,692 shares were represented in person or by proxy.
All seven director nominees — John Sullivan, Siddhartha Kadia, Shiraz Ladiwala, Jennifer “Jenny” Alltoft, Mark Capone, Shannon Hall, and R. Tony Tripeny — were elected to one-year terms, each receiving over 4.35 million votes in favor, with broker non-votes recorded. Shareholders also approved the ratification of Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending March 31, 2027, with 4,814,383 votes for. On a non-binding advisory basis, shareholders approved the compensation of the named executive officers, with 4,317,389 votes for and 136,782 against.
MESA LABORATORIES INC (MLAB) is the issuer of common stock that former officer Gary M. Owens has notified for potential sale under Rule 144. The notice covers up to 20,358 shares of common stock, with an indicated aggregate market value of $2,600,734.50 and shares outstanding of 5,595,869.
The shares to be sold were acquired through multiple restricted stock vesting events between June 2020 and June 2026 as compensation from the issuer. The notice also lists Owens’s prior sales over the past three months, executed through Fidelity Brokerage Services LLC acting as attorney-in-fact.
MESA LABORATORIES INC (MLAB) is the subject of a Rule 144 notice filed for the potential sale of its common stock by former officer Gary M. Owens. The notice covers up to 20,000 shares of common stock to be sold through Fidelity Brokerage Services LLC, with an aggregate market value of $2,450,059.20 and 5,595,869 shares of common stock outstanding as context. The shares were acquired through restricted stock vesting grants between 2018 and 2025. The form also notes a prior sale by Owens of 3,706 shares on June 16, 2026 for $375,295.50.
Mesa Laboratories director Mark Christopher Capone reported the vesting and exercise of 2,784 Restricted Stock Units into an equal number of shares of common stock on August 15, 2026. The derivative RSU position was reduced to zero in this transaction, and his directly held common stock position increased to 6,213 shares.